New Guidelines Offer Clarity in Pediatric Blood Clot Prevention
The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have jointly released comprehensive clinical practice guidelines addressing anticoagulant prophylaxis in non-cardiac pediatric patients at risk of venous thromboembolism (VTE). Published in Blood Advances, these guidelines aim to standardize care for a vulnerable population where preventative strategies have historically lacked consensus.
The Rising Concern of Pediatric VTE
Venous thromboembolism, the formation of blood clots in veins, is becoming increasingly common in children, particularly those hospitalized or managing chronic conditions like cancer. Hospital-acquired VTE is now the second most common cause of preventable harm in children. Previously, much of the data used to guide VTE prevention in pediatric patients was extrapolated from adult studies, which often don’t accurately reflect the unique risk profiles of children.
Key Recommendations for Prophylaxis
The new guidelines, developed by a multidisciplinary expert panel including a lived experience expert, present twelve recommendations and two fine practice statements. These address the complex decision-making process surrounding anticoagulant prophylaxis. Specifically, the guidelines offer conditional recommendations suggesting:
- No anticoagulant prophylaxis for children with solid cancer, trauma, or critical illness.
- Anticoagulant prophylaxis for children with antiphospholipid syndrome or those on long-term total parenteral nutrition.
The guidelines as well provide counsel on administering prophylaxis to children with acute lymphoblastic leukemia, lymphoma, a central venous access device, or those who have recently undergone surgery.
Addressing Gaps in Care and Future Research
Recognizing the necessitate for ongoing improvement, the guidelines emphasize the importance of standardized protocols for managing interruptions to therapy, particularly during procedures like lumbar puncture or spinal anesthesia. The expert panel highlighted the need for further research to develop VTE risk assessment models specifically tailored for pediatric populations and to evaluate the safety and efficacy of prophylaxis across different subgroups of children.
“These guidelines provide physicians with an evidence-based framework to make decisions about VTE prophylaxis for children,” said Marisol Betensky, MD, MPH, co-chair of the guidelines.
The Importance of Collaboration
“This patient group is often among the most vulnerable and medically complex we treat, and clinicians have long lacked clear guidance on how to best care for them,” stated ASH President Robert Negrin, MD. The collaboration between ASH and ISTH underscores a shared commitment to advancing evidence-based care and improving outcomes for children worldwide.
Resources for Healthcare Professionals
Additional resources, including visual summaries and teaching slides, are available at hematology.org/VTE. ASH and ISTH have also previously developed revised clinical practice guidelines for pediatric VTE treatment.
Frequently Asked Questions
What is VTE? VTE stands for venous thromboembolism, which is the formation of blood clots in veins.
Why are these guidelines significant? They provide a standardized approach to preventing blood clots in children, a population where preventative care has been historically unclear.
Where can I find more information? Visit hematology.org/VTE for additional resources.
Pro Tip: Always consider the individual patient’s risk factors and clinical presentation when making decisions about anticoagulant prophylaxis.
Stay informed about the latest advancements in pediatric hematology. Explore more articles on our website and subscribe to our newsletter for updates.
